BALPHARMA105.50

Bal Pharma Limited

· Pharma & Health
₹ CrorePeersALPAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹168 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)176.52250.88263.84263.84
Receivable Days (DSO)107.19111.33109.66109.66
Payable Days (DPO)157.45198.92201.74187.26
Cash Conversion Cycle (days)126.26163.29171.76186.24
Working Capital Turnover10.9119.7223.9625.71
Asset Turnover1.060.900.830.83
Cash Conversion (CFO/Net Income)44.212.881.241.24
CFO/EBITDA10.440.700.250.25
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.